Login to Your Account

Clinic Roundup

Tuesday, July 17, 2012

• Peregrine Pharmaceuticals Inc., of Tustin, Calif., reported that an investigator-sponsored trial of its monocolonal antibody bavituximab for patients with Stage II or Stage III rectal adenocarcinoma has been initiated. The open-label Phase I trial will enroll up to 18 patients to receive the antibody in combination with capcitabine and radiation for eight weeks.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription